Suchergebnisse - "Tugnait, Meera"

1

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

von: Hanley, Michael J.

2023, in: Investigational new drugs

Wird geladen...
2

Effect of severe renal impairment on the pharmacokinetics of brigatinib

von: Gupta, Neeraj

2021, in: Investigational new drugs

Wird geladen...
3

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

von: Eudy Rena J

2011, in: Journal of Translational Medicine

Wird geladen...
4

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

von: Eudy, Rena J

2011, in: Journal of translational medicine

Wird geladen...
5

Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology

von: Maurer, Tristan S.

2011, in: AAPS PharmSci

Wird geladen...
6

Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

von: Tojo, Arinobu

2017, in: International journal of hematology

Wird geladen...
7

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

von: Gettinger, Scott N

2016, in: My

Wird geladen...
8

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

von: Heinrich, Michael C

2020, in: The lancet / Oncology

Wird geladen...
9

Discovery of mobocertinib, a potent, oral inhibitor of

von: Huang, Wei-Sheng

2022, in: Bioorganic & medicinal chemistry letters

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!